BRAF V600E Mutation and Precision Treatment of Colorectal Cancer: New Advances with Two Targeted Medicines

How the BRAF V600E mutation guides treatment in metastatic colorectal cancer, and why encorafenib plus cetuximab, supported by the BEACON CRC and BREAKWATER trials, is an important targeted option.

Top Stories

Teclistamab Approved for a New Indication: A New Advance in Multiple Myeloma Treatment

Over 96% of Patients Experienced Tumor Shrinkage or Complete Disappearance! Takeda's Brentuximab Vedotin Approved for a New First-Line PTCL Indication in China

Latest Coverage

China Pharmaceutical Supplier DengYueMed — A Guide to OTC, Prescription and Specialty Medicines
As the global pharmaceutical supply chain continues to evolve, Chinese medicines and related supply chain services ar...

China Pharmacy Night Services Guide: Where Can Tourists Buy Medicine at Night?
For international visitors traveling, working, or staying in China temporarily, experiencing a cold, headache, allerg...

A Guide to Pharmacies in China: What Medicines Can Foreign Visitors Find?
For foreign tourists, international customers, and people visiting or living in China, understanding Chinese pharmaci...

Ropeginterferon Alfa-2b, a Major Hematology Drug, Expands Its Indications: Essential Thrombocythemia
On October 15, 2026, the official website of China’s National Medical Products Administration (NMPA) indicated that r...

Understanding the Global Pharmaceutical Supply Chain: How Medicines Cross Markets and Borders
Access to medicines is an important issue in global healthcare. For patients, pharmacies, and healthcare institutions...

Zongertinib vs. Sevabertinib: Two Major Breakthroughs in HER2-Mutant Lung Cancer Treatment — What Are the Key Differences?
Beginning in 2025, zongertinib became the first oral targeted therapy approved worldwide for HER2-mutant NSCLC. Sevab...

In-Depth Analysis

BRAF V600E Mutation and Precision Treatment of Colorectal Cancer: New Advances with Two Targeted Medicines

Teclistamab Approved for a New Indication: A New Advance in Multiple Myeloma Treatment

Over 96% of Patients Experienced Tumor Shrinkage or Complete Disappearance! Takeda's Brentuximab Vedotin Approved for a New First-Line PTCL Indication in China

China Pharmaceutical Supplier DengYueMed — A Guide to OTC, Prescription and Specialty Medicines